Showing results (641-650 of 3,716) with videos related to

Sort By:
Pageof 372
Investigational New Drugs|April 27, 2007
Taurolidine: a novel anti-neoplastic agent induces apoptosis of osteosarcoma cell linesDenise K Walters, Roman Muff, Bettina Langsam, et al.
Investigational New Drugs|September 6, 2007
Intravenous ATP infusions can be safely administered in the home setting: a study in pre-terminal cancer patientsSandra Beijer, Eric A R Gielisse, Pierre S Hupperets, et al.
Investigational New Drugs|February 28, 2006
Phase II trial of DNA methyltransferase 1 inhibition with the antisense oligonucleotide MG98 in patients with metastatic renal carcinoma: a National Cancer Institute of Canada Clinical Trials Group investigational new drug studyEric Winquist, Jennifer Knox, Jean-Pierre Ayoub, et al.
Investigational New Drugs|February 28, 2006
A phase I clinical and pharmacokinetic study of CS-682 administered orally in advanced malignant solid tumorsThierry Delaunoit, Patrick A Burch, Joel M Reid, et al.
Investigational New Drugs|March 11, 2009
Silibinin ameliorates oxidative stress induced aberrant crypt foci and lipid peroxidation in 1, 2 dimethylhydrazine induced rat colon cancerNagarajan Sangeetha, Selvaraj Aranganathan, Namasivayam Nalini
Investigational New Drugs|March 11, 2009
FBA-TPQ, a novel marine-derived compound as experimental therapy for prostate cancerFeng Wang, Scharri J Ezell, Yong Zhang, et al.
Investigational New Drugs|May 8, 2009
Phase II study of gemcitabine for treatment of patients with advanced stage marginal zone B-cell lymphoma: Consortium for Improving Survival of Lymphoma (CISL) trialSung Yong Oh, Won Seog Kim, Dae Ho Lee, et al.
Investigational New Drugs|May 22, 2009
The neem limonoids azadirachtin and nimbolide inhibit cell proliferation and induce apoptosis in an animal model of oral oncogenesisG Harish Kumar, R Vidya Priyadarsini, G Vinothini, et al.
Investigational New Drugs|June 6, 2009
Reversible cardiogenic shock following 5-fluorouracil infusionCharles Ferté, Carlos Gomez Roca, Yohann Loriot, et al.
Investigational New Drugs|June 6, 2009
Tyrosine kinase inhibitors potentiate the cytotoxicity of MDR-substrate anticancer agents independent of growth factor receptor status in lung cancer cell linesD M Collins, J Crown, N O'Donovan, et al.
Pageof 372